Skip to main content
. Author manuscript; available in PMC: 2015 Feb 4.
Published in final edited form as: Clin Cancer Res. 2014 Oct 9;21(3):495–497. doi: 10.1158/1078-0432.CCR-14-1776

Figure 1.

Figure 1

Therapeutic agents that are either FDA-approved or currently in clinical trials targeting the genetic aberrations found in HNSCC determined by Seiwert and colleagues (1). Red: oncogenes, Black: tumor suppressors, Blue box: HPV(−) tumors, Green box: HPV(+) tumors. The incidence of mutations (M) and amplifications (A) are separated by HPV status. Adapted from Seiwert et al. (1).